Mast cell leukemia pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Nawal Muazam (talk | contribs) No edit summary |
Nawal Muazam (talk | contribs) No edit summary |
||
Line 9: | Line 9: | ||
*Adult-type human mastocytosis is characterized by mutations in c-KIT at codon 816, which cause constitutive activation of KIT kinase. | *Adult-type human mastocytosis is characterized by mutations in c-KIT at codon 816, which cause constitutive activation of KIT kinase. | ||
*Different classes of activating KIT mutations respond differentially to KIT inhibitors depending on the site and type of mutation. | *Different classes of activating KIT mutations respond differentially to KIT inhibitors depending on the site and type of mutation. | ||
*D816V c-KIT mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients. | *D816V c-KIT mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.<ref name="JorisGeorgin-Lavialle2012">{{cite journal|last1=Joris|first1=Magalie|last2=Georgin-Lavialle|first2=Sophie|last3=Chandesris|first3=Marie-Olivia|last4=Lhermitte|first4=Ludovic|last5=Claisse|first5=Jean-François|last6=Canioni|first6=Danielle|last7=Hanssens|first7=Katia|last8=Damaj|first8=Gandhi|last9=Hermine|first9=Olivier|last10=Hamidou|first10=Mohammed|title=Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive|journal=Case Reports in Hematology|volume=2012|year=2012|pages=1–6|issn=2090-6560|doi=10.1155/2012/517546}}</ref> | ||
==Associated Conditions== | ==Associated Conditions== | ||
==Gross Pathology== | ==Gross Pathology== | ||
==Microscopic Pathology== | ==Microscopic Pathology== | ||
==Immunohistochemistry== | ==Immunohistochemistry== | ||
*Atypical mast cells express multiple surface antigens such as: | *Atypical mast cells express multiple surface antigens such as:<ref name="JorisGeorgin-Lavialle2012">{{cite journal|last1=Joris|first1=Magalie|last2=Georgin-Lavialle|first2=Sophie|last3=Chandesris|first3=Marie-Olivia|last4=Lhermitte|first4=Ludovic|last5=Claisse|first5=Jean-François|last6=Canioni|first6=Danielle|last7=Hanssens|first7=Katia|last8=Damaj|first8=Gandhi|last9=Hermine|first9=Olivier|last10=Hamidou|first10=Mohammed|title=Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive|journal=Case Reports in Hematology|volume=2012|year=2012|pages=1–6|issn=2090-6560|doi=10.1155/2012/517546}}</ref> | ||
:*CD117/kit | :*CD117/kit | ||
:*CD11c | :*CD11c | ||
:*CD13 | :*CD13 | ||
:*CD29 | :*CD29 | ||
:*CD33 | :*CD33 | ||
:*CD44 | :*CD44 | ||
:*CD45 | :*CD45 | ||
:*CD63 | :*CD63 | ||
:*CD68 | :*CD68 | ||
:*CD71 | :*CD71 | ||
:*CD2 | :*CD2 | ||
:*CD22 | :*CD22 | ||
:*CD25 | :*CD25 | ||
:*CD54 | :*CD54 | ||
*The role of these antigens is however not yet understood. | *The role of these antigens is however not yet understood. | ||
*CD2 and CD25 antigens are important markers and their positivity on the surface of mast cells constitute minor criteria for the diagnosis of mast cell disease. | *CD2 and CD25 antigens are important markers and their positivity on the surface of mast cells constitute minor criteria for the diagnosis of mast cell disease. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 15:05, 25 November 2015
Mast cell leukemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Mast cell leukemia pathophysiology On the Web |
American Roentgen Ray Society Images of Mast cell leukemia pathophysiology |
Risk calculators and risk factors for Mast cell leukemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
Pathophysiology
Pathogenesis
Genetics
- Mutation of c-KIT is also a hallmark of the disease.
- Adult-type human mastocytosis is characterized by mutations in c-KIT at codon 816, which cause constitutive activation of KIT kinase.
- Different classes of activating KIT mutations respond differentially to KIT inhibitors depending on the site and type of mutation.
- D816V c-KIT mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.[1]
Associated Conditions
Gross Pathology
Microscopic Pathology
Immunohistochemistry
- Atypical mast cells express multiple surface antigens such as:[1]
- CD117/kit
- CD11c
- CD13
- CD29
- CD33
- CD44
- CD45
- CD63
- CD68
- CD71
- CD2
- CD22
- CD25
- CD54
- The role of these antigens is however not yet understood.
- CD2 and CD25 antigens are important markers and their positivity on the surface of mast cells constitute minor criteria for the diagnosis of mast cell disease.
References
- ↑ 1.0 1.1 Joris, Magalie; Georgin-Lavialle, Sophie; Chandesris, Marie-Olivia; Lhermitte, Ludovic; Claisse, Jean-François; Canioni, Danielle; Hanssens, Katia; Damaj, Gandhi; Hermine, Olivier; Hamidou, Mohammed (2012). "Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive". Case Reports in Hematology. 2012: 1–6. doi:10.1155/2012/517546. ISSN 2090-6560.